A delegation from the Indian Pharmacopoeia Commission (IPC), Ministry of Health and Family Welfare, Government of India, led by Dr. V Kalaiselvan, Secretary-cum-Scientific Director, along with Dr. Pawan Saini and Dr. Shruti Rastogi, participated in the 16th International Meeting of World Pharmacopoeias (IMWP) and the accompanying Stakeholders’ Meeting held in Brasília, Brazil, from June 15 to 17, 2026.

The meeting, coordinated by the World Health Organization (WHO), brought together representatives from pharmacopoeias worldwide, including the Brazilian Pharmacopoeia (Brazil), European Pharmacopoeia (Europe), Indian Pharmacopoeia (India), Japanese Pharmacopoeia (Japan), Korean Pharmacopoeia (Republic of Korea), Mexican Pharmacopoeia (Mexico), Russian Pharmacopoeia (Russian Federation), British Pharmacopoeia (United Kingdom), US Pharmacopeia (United States of America), State Pharmacopoeia of the Republic of Uzbekistan (Uzbekistan), Vietnamese Pharmacopoeia (Vietnam) and The International Pharmacopoeia of WHO.

During the meeting, Dr. Kalaiselvan presented key updates on the Indian Pharmacopoeia (IP), highlighting recent advancements in pharmacopoeial standards, modernisation initiatives, and India's contributions toward global harmonisation of medicine quality standards. Discussions during the meeting reaffirmed that the standards of the IP are comparable with international pharmacopoeias. India was also recognised for its leadership in developing and establishing quality standards for anti-tuberculosis medicines, anti-cancer therapeutics, blood and blood products, medicines used in the management of anemia, and other complex pharmaceutical molecules, reflecting the country's growing scientific, regulatory, and pharmacopoeial capabilities.

The Indian delegation actively contributed to discussions on modern microbiological methods, pharmacopoeial convergence, and environmental sustainability in pharmaceutical standards.

At the stakeholders’ meeting, Dr. Kalaiselvan showcased its role in strengthening public health through science-based standards and regulatory support, while emphasising the importance of international cooperation in ensuring the quality, safety, and efficacy of medicines worldwide. India’s participation at the 16th IMWP further strengthened collaboration with international pharmacopoeias and reaffirmed the country’s growing leadership in shaping global pharmaceutical quality standards for the benefit of patients worldwide.